A government review's six-year-old recommendations led to the decision to fund an unapproved and unapprovable product over an approved medicine. The document is the first in a series that ended with an unprecedented workaround on patient safety...

International comparisons can work both ways, the incredibly disrespectful and dismissive 'let them eat cake' attitudes of two key advisory committees and a welcome ministerial intervention that should be more broadly applied. We also answer so...

There was quite a bit of eminence this week in the public discussion about access to health technologies. Some personal and wider reflections on the role of prejudice in funding and reimbursement decisions.

We draw a line between some very careful use of language by small 'g' government officials that clearly connects some recent processes and events. It could be a coincidence, but it's remarkable and very convenient. Everything happens for a reas...

It's another week of debate over PBS deferrals. Unfortunately, there appears to be an effort to limit public discussion. Given the obvious risk to patients and the implications for the access agenda, which is flailing against the backdrop of de...